bioMérieux and GSK team up for breast cancer theranostic
This article was originally published in Clinica
French diagnostics company bioMérieux is collaborating with pharma giant GlaxoSmithKline (GSK) to develop a predictive test that will provide more customised treatment for breast cancer patients. Both companies will co-fund the development activities. The test, based on emerging biomarkers, will be designed for use in both adjuvant and metastatic breast cancer cases.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.